nisoldipine has been researched along with Hypertrophy in 2 studies
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.
nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.
methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.
Hypertrophy: General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Chronic treatment of SHR with nisoldipine at doses that blocked the development of hypertension and attenuated the concomitant hypertrophy of heart and aorta, or in vitro pretreatment of SHR arteries with nisoldipine, decreased the contractile force developed by arteries in response to KCl depolarization and normalized the subsequent relaxation." | 3.68 | Effects of a chronic treatment by nisoldipine, a calcium antagonistic dihydropyridine, on arteries of spontaneously hypertensive rats. ( Godfraind, T; Kazda, S; Wibo, M, 1991) |
| "Cell hypertrophy was induced by reapplication of 1% fatal bovine serum (FBS) following a period (24 h) of FBS depletion." | 1.35 | T-type Ca2+ channel blockers prevent cardiac cell hypertrophy through an inhibition of calcineurin-NFAT3 activation as well as L-type Ca2+ channel blockers. ( Hojo, M; Horiba, M; Kamiya, K; Kodama, I; Lee, JK; Miwa, K; Muto, T; Opthof, T; Ueda, N; Yasui, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horiba, M | 1 |
| Muto, T | 1 |
| Ueda, N | 1 |
| Opthof, T | 1 |
| Miwa, K | 1 |
| Hojo, M | 1 |
| Lee, JK | 1 |
| Kamiya, K | 1 |
| Kodama, I | 1 |
| Yasui, K | 1 |
| Godfraind, T | 1 |
| Kazda, S | 1 |
| Wibo, M | 1 |
2 other studies available for nisoldipine and Hypertrophy
| Article | Year |
|---|---|
T-type Ca2+ channel blockers prevent cardiac cell hypertrophy through an inhibition of calcineurin-NFAT3 activation as well as L-type Ca2+ channel blockers.
Topics: Active Transport, Cell Nucleus; Animals; Calcineurin; Calcium Channel Blockers; Calcium Channels, L- | 2008 |
Effects of a chronic treatment by nisoldipine, a calcium antagonistic dihydropyridine, on arteries of spontaneously hypertensive rats.
Topics: Animals; Aorta; Brain; Calcium Channel Blockers; Calcium Channels; Dihydropyridines; Hypertrophy; Me | 1991 |